|
WO2020254675A1
|
|
Parenteral lysophosphatidylcholine formulations such as lpc-dha, lpc-epa and their use in therapy
|
|
NL2023407B1
|
|
Parenteral lysophosphatidylcholine formulations
|
|
WO2019150197A1
|
|
Marine protein hydrolysate with low fluoride and trimethylamin content
|
|
EP3727037A1
|
|
Lysophosphatidylcholine compositions
|
|
WO2017029558A2
|
|
Methods for improving health of farmed fish
|
|
KR20170117476A
|
|
Lipid composition
|
|
KR20170118125A
|
|
Lipid extraction process
|
|
US2016175366A1
|
|
Enhanced omega-3 formulations
|
|
US2015343000A1
|
|
Methods for improving fillet quality in farmed fish
|
|
AU2015265623A1
|
|
Krill oil preparations and their uses
|
|
AU2015216691A1
|
|
Krill oil preparations with optimal mineral and metal composition, low impurities and low and stable TMA levels
|
|
AU2014203179A1
|
|
Lipid extraction processes
|
|
US2014363517A1
|
|
Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders
|
|
AU2014229540A1
|
|
Omega- 3 phospholipid supplements for improved brain maturity
|
|
EP3756658A1
|
|
Omega -3 compositions
|
|
CN105578928A
|
|
Lipid extraction processes
|
|
EP2874500A2
|
|
Concentration of omega-3 polyunsaturated fatty acids in krill oil
|
|
AU2013206138A1
|
|
Phospholipid and protein tablets
|
|
AU2013205514A1
|
|
Natural marine source phospholipids comprising flavonoids, polyunsaturated fatty acids and their applications
|
|
US2015030718A1
|
|
Oxidixable fatty acid composition delivery form
|
